Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01705977




Registration number
NCT01705977
Ethics application status
Date submitted
10/10/2012
Date registered
15/10/2012
Date last updated
15/07/2024

Titles & IDs
Public title
Belimumab Assessment of Safety in SLE
Scientific title
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Secondary ID [1] 0 0
2011-005667-25
Secondary ID [2] 0 0
115467
Universal Trial Number (UTN)
Trial acronym
BASE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Systemic Lupus Erythematosus 0 0
Condition category
Condition code
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Placebo plus standard therapy
Treatment: Other - Belimumab 10 mg/kg plus standard therapy
Other interventions - Standard therapy

Placebo comparator: Placebo plus standard therapy - Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period.

Experimental: Belimumab 10 mg/kg plus standard therapy - Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period.


Treatment: Other: Placebo plus standard therapy
Placebo plus standard therapy

Treatment: Other: Belimumab 10 mg/kg plus standard therapy
Belimumab 10 mg/kg plus standard therapy

Other interventions: Standard therapy
Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; other biologics are not permitted.
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Deaths - On Treatment Period (Week 52)
Timepoint [1] 0 0
Up to Week 52 (On-treatment period)
Primary outcome [2] 0 0
Number of Participants Who Reported Protocol Defined Adverse Events of Special Interest (AESI): On-treatment Period (Week 52)
Timepoint [2] 0 0
Up to Week 52 (On-treatment period)
Primary outcome [3] 0 0
Number of Participants With Serious Adverse Events (SAEs) Reported During On-treatment Period (Week 52)
Timepoint [3] 0 0
Up to Week 52 (On-treatment period)
Secondary outcome [1] 0 0
Number of Deaths Reported - On-study Period (Week 52)
Timepoint [1] 0 0
Up to Week 52 (On-study period)
Secondary outcome [2] 0 0
Number of Participants Who Reported Protocol Defined AESI: On-study Period (Week 52)
Timepoint [2] 0 0
Up to Week 52 (On-study period)
Secondary outcome [3] 0 0
Number of Participants With SAEs Reported During On-study Period (Week 52)
Timepoint [3] 0 0
Up to Week 52 (On-study period)
Secondary outcome [4] 0 0
Percentage of Participants Whose Average Prednisone (or Equivalent) Dose to Treat SLE Has Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Weeks 40 Through 52
Timepoint [4] 0 0
Week 40 to Week 52
Secondary outcome [5] 0 0
Number of Participants With All-cause Mortality During Years 2 to 5
Timepoint [5] 0 0
From 2 years to 5 years
Secondary outcome [6] 0 0
Number of Participants With New Primary Malignancies During Years 2 to 5
Timepoint [6] 0 0
From 2 years to 5 years

Eligibility
Key inclusion criteria
Key

* Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria.
* Active SLE disease.
* Autoantibody-positive.
* On stable SLE treatment regimen which may include corticosteroids (for example, prednisone), antimalarial (for example, hydroxychloroquine) and/or immunosuppressants (for example, azathioprine, methotrexate, mycophenolate).

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Pregnant or nursing.
* Have received treatment with any of the following: belimumab, either as a marketed product or as an investigational agent; any B cell targeted therapy (for example, rituximab) in the past year; or any biological agent (for example, adalimumab, etanercept, infliximab, or anakinra) in the past 90 days.
* Have received a live vaccine within the past 30 days.
* Have severe active lupus kidney disease.
* Have severe active central nervous system (CNS) lupus.
* Current or past positive for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
27/11/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
10/08/2022
Sample size
Target
Accrual to date
Final
4019
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,VIC
Recruitment hospital [1] 0 0
GSK Investigational Site - Garran
Recruitment hospital [2] 0 0
GSK Investigational Site - Sydney
Recruitment hospital [3] 0 0
GSK Investigational Site - Herston
Recruitment hospital [4] 0 0
GSK Investigational Site - Fitzroy
Recruitment postcode(s) [1] 0 0
2605 - Garran
Recruitment postcode(s) [2] 0 0
2153 - Sydney
Recruitment postcode(s) [3] 0 0
4029 - Herston
Recruitment postcode(s) [4] 0 0
3065 - Fitzroy
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Iowa
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
Mississippi
Country [8] 0 0
United States of America
State/province [8] 0 0
Montana
Country [9] 0 0
United States of America
State/province [9] 0 0
Nevada
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
North Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
South Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Tennessee
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
United States of America
State/province [17] 0 0
Virginia
Country [18] 0 0
United States of America
State/province [18] 0 0
Washington
Country [19] 0 0
United States of America
State/province [19] 0 0
West Virginia
Country [20] 0 0
Argentina
State/province [20] 0 0
Buenos Aires
Country [21] 0 0
Argentina
State/province [21] 0 0
Santa Fe
Country [22] 0 0
Argentina
State/province [22] 0 0
Tucumán
Country [23] 0 0
Argentina
State/province [23] 0 0
Cordoba
Country [24] 0 0
Argentina
State/province [24] 0 0
Mendoza
Country [25] 0 0
Argentina
State/province [25] 0 0
Tucuman
Country [26] 0 0
Brazil
State/province [26] 0 0
Mato Grosso
Country [27] 0 0
Brazil
State/province [27] 0 0
Minas Gerais
Country [28] 0 0
Brazil
State/province [28] 0 0
Paraná
Country [29] 0 0
Brazil
State/province [29] 0 0
Rio Grande Do Sul
Country [30] 0 0
Brazil
State/province [30] 0 0
Santa Catarina
Country [31] 0 0
Brazil
State/province [31] 0 0
São Paulo
Country [32] 0 0
Brazil
State/province [32] 0 0
Belo Horizonte, Minas Gerais
Country [33] 0 0
Brazil
State/province [33] 0 0
Campinas
Country [34] 0 0
Brazil
State/province [34] 0 0
Campo Grande
Country [35] 0 0
Brazil
State/province [35] 0 0
Goiania
Country [36] 0 0
Brazil
State/province [36] 0 0
Lajeado
Country [37] 0 0
Brazil
State/province [37] 0 0
Rio de Janeiro
Country [38] 0 0
Brazil
State/province [38] 0 0
Salvador
Country [39] 0 0
Bulgaria
State/province [39] 0 0
Pleven
Country [40] 0 0
Bulgaria
State/province [40] 0 0
Plovdiv
Country [41] 0 0
Bulgaria
State/province [41] 0 0
Ruse
Country [42] 0 0
Bulgaria
State/province [42] 0 0
Shumen
Country [43] 0 0
Bulgaria
State/province [43] 0 0
Sofia
Country [44] 0 0
Bulgaria
State/province [44] 0 0
Stara Zagora
Country [45] 0 0
Bulgaria
State/province [45] 0 0
Targovisthe
Country [46] 0 0
Bulgaria
State/province [46] 0 0
Veliko Tarnovo
Country [47] 0 0
Canada
State/province [47] 0 0
Ontario
Country [48] 0 0
Chile
State/province [48] 0 0
La Serena
Country [49] 0 0
Chile
State/province [49] 0 0
Santigo
Country [50] 0 0
Colombia
State/province [50] 0 0
Armenia
Country [51] 0 0
Colombia
State/province [51] 0 0
Barranquilla
Country [52] 0 0
Colombia
State/province [52] 0 0
Bogota
Country [53] 0 0
Colombia
State/province [53] 0 0
Bucaramanga
Country [54] 0 0
Colombia
State/province [54] 0 0
Chia
Country [55] 0 0
Colombia
State/province [55] 0 0
Medellin
Country [56] 0 0
Croatia
State/province [56] 0 0
Osijek
Country [57] 0 0
Croatia
State/province [57] 0 0
Rijeka
Country [58] 0 0
Czechia
State/province [58] 0 0
Brno
Country [59] 0 0
Czechia
State/province [59] 0 0
Praha 2
Country [60] 0 0
Czechia
State/province [60] 0 0
Praha 5
Country [61] 0 0
Czechia
State/province [61] 0 0
Zlin
Country [62] 0 0
Estonia
State/province [62] 0 0
Tallinn
Country [63] 0 0
Hong Kong
State/province [63] 0 0
Hong Kong
Country [64] 0 0
Hong Kong
State/province [64] 0 0
Shatin
Country [65] 0 0
Hungary
State/province [65] 0 0
Budapest
Country [66] 0 0
Hungary
State/province [66] 0 0
Debrecen
Country [67] 0 0
Hungary
State/province [67] 0 0
Gyula
Country [68] 0 0
Hungary
State/province [68] 0 0
Zalaegerszeg
Country [69] 0 0
Indonesia
State/province [69] 0 0
Bandung
Country [70] 0 0
Indonesia
State/province [70] 0 0
Denpasar
Country [71] 0 0
Indonesia
State/province [71] 0 0
Malang
Country [72] 0 0
Indonesia
State/province [72] 0 0
Palembang
Country [73] 0 0
Indonesia
State/province [73] 0 0
Yogyakarta
Country [74] 0 0
Italy
State/province [74] 0 0
Lazio
Country [75] 0 0
Italy
State/province [75] 0 0
Lombardia
Country [76] 0 0
Italy
State/province [76] 0 0
Toscana
Country [77] 0 0
Italy
State/province [77] 0 0
Veneto
Country [78] 0 0
Italy
State/province [78] 0 0
Pisa
Country [79] 0 0
Korea, Republic of
State/province [79] 0 0
Daegu
Country [80] 0 0
Korea, Republic of
State/province [80] 0 0
Daejeon
Country [81] 0 0
Korea, Republic of
State/province [81] 0 0
Gwangju
Country [82] 0 0
Korea, Republic of
State/province [82] 0 0
Incheon
Country [83] 0 0
Korea, Republic of
State/province [83] 0 0
Jeonju-si
Country [84] 0 0
Korea, Republic of
State/province [84] 0 0
Seoul
Country [85] 0 0
Korea, Republic of
State/province [85] 0 0
Suwon-si
Country [86] 0 0
Korea, Republic of
State/province [86] 0 0
Suwon
Country [87] 0 0
Lithuania
State/province [87] 0 0
Klaipeda
Country [88] 0 0
Malaysia
State/province [88] 0 0
Ipoh
Country [89] 0 0
Malaysia
State/province [89] 0 0
Kota Bahru
Country [90] 0 0
Malaysia
State/province [90] 0 0
Kota Kinabalu
Country [91] 0 0
Malaysia
State/province [91] 0 0
Kuala Lumpur
Country [92] 0 0
Malaysia
State/province [92] 0 0
Kuala Terengganu
Country [93] 0 0
Malaysia
State/province [93] 0 0
Selangor
Country [94] 0 0
Malaysia
State/province [94] 0 0
Seremban, Negeri Sembilan
Country [95] 0 0
Mexico
State/province [95] 0 0
Coahuila
Country [96] 0 0
Mexico
State/province [96] 0 0
Estado De México
Country [97] 0 0
Mexico
State/province [97] 0 0
Jalisco
Country [98] 0 0
Mexico
State/province [98] 0 0
Nuevo León
Country [99] 0 0
Mexico
State/province [99] 0 0
Yucatán
Country [100] 0 0
Mexico
State/province [100] 0 0
D.F
Country [101] 0 0
Mexico
State/province [101] 0 0
Guadalajara
Country [102] 0 0
Mexico
State/province [102] 0 0
Mexico
Country [103] 0 0
Mexico
State/province [103] 0 0
San Luis Potosí
Country [104] 0 0
Mexico
State/province [104] 0 0
Torreon
Country [105] 0 0
New Zealand
State/province [105] 0 0
Auckland
Country [106] 0 0
New Zealand
State/province [106] 0 0
Wellington
Country [107] 0 0
Peru
State/province [107] 0 0
Arequipa
Country [108] 0 0
Peru
State/province [108] 0 0
Lima
Country [109] 0 0
Philippines
State/province [109] 0 0
Angeles City, Pampanga
Country [110] 0 0
Philippines
State/province [110] 0 0
Cebu City
Country [111] 0 0
Philippines
State/province [111] 0 0
Davao City
Country [112] 0 0
Philippines
State/province [112] 0 0
Iloilo City
Country [113] 0 0
Philippines
State/province [113] 0 0
Las Pinas
Country [114] 0 0
Philippines
State/province [114] 0 0
Manila
Country [115] 0 0
Philippines
State/province [115] 0 0
Quezon City
Country [116] 0 0
Poland
State/province [116] 0 0
Bydgoszcz
Country [117] 0 0
Poland
State/province [117] 0 0
Gdansk
Country [118] 0 0
Poland
State/province [118] 0 0
Krakow
Country [119] 0 0
Portugal
State/province [119] 0 0
Almada
Country [120] 0 0
Portugal
State/province [120] 0 0
Coimbra
Country [121] 0 0
Portugal
State/province [121] 0 0
Lisboa
Country [122] 0 0
Portugal
State/province [122] 0 0
Porto
Country [123] 0 0
Portugal
State/province [123] 0 0
Viseu
Country [124] 0 0
Romania
State/province [124] 0 0
Bucharest
Country [125] 0 0
Romania
State/province [125] 0 0
Galati
Country [126] 0 0
Romania
State/province [126] 0 0
Targu Mures
Country [127] 0 0
Russian Federation
State/province [127] 0 0
Barnaul
Country [128] 0 0
Russian Federation
State/province [128] 0 0
Kemerovo
Country [129] 0 0
Russian Federation
State/province [129] 0 0
Kursk
Country [130] 0 0
Russian Federation
State/province [130] 0 0
Moscow
Country [131] 0 0
Russian Federation
State/province [131] 0 0
Saint-Petersburg
Country [132] 0 0
Russian Federation
State/province [132] 0 0
Saratov
Country [133] 0 0
Russian Federation
State/province [133] 0 0
St. Petersburg
Country [134] 0 0
Serbia
State/province [134] 0 0
Belgrade
Country [135] 0 0
Serbia
State/province [135] 0 0
Krusevac
Country [136] 0 0
Serbia
State/province [136] 0 0
Niska Banja
Country [137] 0 0
Serbia
State/province [137] 0 0
Sabac
Country [138] 0 0
Slovakia
State/province [138] 0 0
Piestany
Country [139] 0 0
Spain
State/province [139] 0 0
Barcelona
Country [140] 0 0
Spain
State/province [140] 0 0
Bilbao
Country [141] 0 0
Spain
State/province [141] 0 0
Castellón
Country [142] 0 0
Spain
State/province [142] 0 0
Cordoba
Country [143] 0 0
Spain
State/province [143] 0 0
Getafe/Madrid
Country [144] 0 0
Spain
State/province [144] 0 0
Granada
Country [145] 0 0
Spain
State/province [145] 0 0
Madrid
Country [146] 0 0
Spain
State/province [146] 0 0
Malaga
Country [147] 0 0
Spain
State/province [147] 0 0
Sevilla
Country [148] 0 0
Spain
State/province [148] 0 0
Seville
Country [149] 0 0
Spain
State/province [149] 0 0
Valencia
Country [150] 0 0
Spain
State/province [150] 0 0
Vilajoyosa
Country [151] 0 0
Switzerland
State/province [151] 0 0
St. Gallen
Country [152] 0 0
Switzerland
State/province [152] 0 0
Zuerich
Country [153] 0 0
Taiwan
State/province [153] 0 0
Chiayi County
Country [154] 0 0
Taiwan
State/province [154] 0 0
Gueishan Township,Taoyuan County
Country [155] 0 0
Taiwan
State/province [155] 0 0
Kaohsiung
Country [156] 0 0
Taiwan
State/province [156] 0 0
Taichung
Country [157] 0 0
Taiwan
State/province [157] 0 0
Taipei
Country [158] 0 0
Thailand
State/province [158] 0 0
Bangkok
Country [159] 0 0
Thailand
State/province [159] 0 0
Chiang Mai
Country [160] 0 0
Ukraine
State/province [160] 0 0
Chernivtsi
Country [161] 0 0
Ukraine
State/province [161] 0 0
Donetsk
Country [162] 0 0
Ukraine
State/province [162] 0 0
Ivano-Frankivsk
Country [163] 0 0
Ukraine
State/province [163] 0 0
Kharkiv
Country [164] 0 0
Ukraine
State/province [164] 0 0
Kyiv
Country [165] 0 0
Ukraine
State/province [165] 0 0
Lviv
Country [166] 0 0
Ukraine
State/province [166] 0 0
Odesa
Country [167] 0 0
Ukraine
State/province [167] 0 0
Poltava
Country [168] 0 0
Ukraine
State/province [168] 0 0
Ternopil
Country [169] 0 0
Ukraine
State/province [169] 0 0
Uzhgorod
Country [170] 0 0
Ukraine
State/province [170] 0 0
Vinnytsia
Country [171] 0 0
Ukraine
State/province [171] 0 0
Vinnytsya
Country [172] 0 0
Ukraine
State/province [172] 0 0
Zaporizhzhia

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to further enhance the existing knowledge regarding the side effects of belimumab when given with other lupus medicines to adults with active systemic lupus erythematosus (SLE). This study mainly focuses on collecting information on serious events that are not that common or may only be seen with long-term treatment. These events include death, serious infections and other infections of interest, cancers, serious mental health problems, including depression and suicide, and serious infusion and hypersensitivity reactions. This study is being done to help understand if treatment with belimumab increases the risk for these types of events. This study will also see if patients receiving belimumab with other lupus medicines can reduce their use of steroids, such as prednisone, over 1 year.
Trial website
https://clinicaltrials.gov/study/NCT01705977
Trial related presentations / publications
Sheikh S, Scheinberg MA, Wei CC, Tegzova D, Stohl W, Acayaba de Toledo R, Mucenic T, Abello M, Maksimowicz-McKinnon K, Abud Mendoza C, Navarra S, Garcia M, Garcia de la Torre I, Ordi Ros J, Nami A, Levy R, Bass D, Ross J, Punwaney R, Harris J, Pierce A, Thorneloe K, Ji B, Roth D. Mortality and adverse events of special interest in adult patients with active, auto-antibody-positive systemic lupus erythematosus receiving intravenous belimumab (BASE): a global, randomised, double-blind, placebo-controlled, multicentre Phase 4 trial. Lancet Rheumatol. 2020; DOI: 10.1016/S2665-9913(20)30355-6
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01705977